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We thank Dr Hasbal for the concern expressed (1) regarding hydroxychloroquine (HCQ) as the
cause of the TMA in our published case titled “Thrombotic microangiopathy (TMA) in a patient with

of

COVID-19”(2). An immune mediated thrombotic microangiopathy usually requires ongoing exposure to

ro

the drug. In our case, the patient mentioned was on HCQ for a duration of 5 days. The initial 2 doses

-p

were prior to the admission and the drug was continued during the initial 3 days of hospitalization. The

re

findings of hemolysis and TMA developed on day 17 of the admission which was 2 weeks after the drug

lP

had been discontinued. Both in the Fromm et al (3) and Mar et al (4) reports that were mentioned, TMA
developed during the duration of treatment with HCQ. In addition, the most commonly used indication

ur

systemic TMA (5).

na

for HCQ is systemic lupus erythematosus (SLE); and we have to keep in mind that SLE can also lead to

Jo

In our case, given the short course of HCQ and stability of hemolysis labs for 2 weeks and the
delayed development of TMA, weeks after the drug was discontinued, suggest against the possibility of
HCQ related TMA.
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